A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

Taimur Sher, Sikander Ailawadhi, Kena C. Miller, Debbie Manfredi, Margaret Wood, Wei Tan, Gregory Wilding, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri, Fredrick Hong, Raman Sood, Saif Soniwala, William Lawrence, Saad Jamshed, Aisha Masood, Daniel Iancu, Kelvin Lee, Asher A Chanan Khan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other anti-myeloma agents, these compounds significantly enhance clinical efficacy. High-dose steroids are frequently used in anti-myeloma combination regimens; however, the doses employed are often poorly tolerated, especially in patients with concurrent comorbid conditions. We hypothesized that a steroid-independent combination regimen could be developed without significant compromise of efficacy. The availability of such a regimen will be important for patients whose concurrent ailments make them poor candidates for steroid containing anti-myeloma regimens. A phase II single institute, non-randomized clinical trial was conducted to investigate a novel steroid-free three-drug combination of bortezomib (V), pegylated liposomal doxorubicin (D), and thalidomide (T), the VDT regimen. Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study. The overall response rate and complete response (CR)+near complete response (nCR) rate was 78% and 35%, respectively. Median time to progression was 29·5months. Fatigue, rash, neuropathy, constipation and infections were the most common side effects. We concluded that VDT is a tolerable and an effective regimen capable of inducing high response rates and can be employed in patients considered to be poor candidates for steroid-based treatment regimens.

Original languageEnglish (US)
Pages (from-to)104-110
Number of pages7
JournalBritish Journal of Haematology
Volume154
Issue number1
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Thalidomide
Multiple Myeloma
Steroids
Drug Combinations
Constipation
Exanthema
Fatigue
Therapeutics
liposomal doxorubicin
Bortezomib
Infection

Keywords

  • Clinical trials
  • Multiple myeloma
  • Newly diagnosed multiple myeloma
  • Steroids
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. / Sher, Taimur; Ailawadhi, Sikander; Miller, Kena C.; Manfredi, Debbie; Wood, Margaret; Tan, Wei; Wilding, Gregory; Czuczman, Myron S.; Hernandez-Ilizaliturri, Francisco J.; Hong, Fredrick; Sood, Raman; Soniwala, Saif; Lawrence, William; Jamshed, Saad; Masood, Aisha; Iancu, Daniel; Lee, Kelvin; Chanan Khan, Asher A.

In: British Journal of Haematology, Vol. 154, No. 1, 07.2011, p. 104-110.

Research output: Contribution to journalArticle

Sher, T, Ailawadhi, S, Miller, KC, Manfredi, D, Wood, M, Tan, W, Wilding, G, Czuczman, MS, Hernandez-Ilizaliturri, FJ, Hong, F, Sood, R, Soniwala, S, Lawrence, W, Jamshed, S, Masood, A, Iancu, D, Lee, K & Chanan Khan, AA 2011, 'A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients', British Journal of Haematology, vol. 154, no. 1, pp. 104-110. https://doi.org/10.1111/j.1365-2141.2011.08703.x
Sher, Taimur ; Ailawadhi, Sikander ; Miller, Kena C. ; Manfredi, Debbie ; Wood, Margaret ; Tan, Wei ; Wilding, Gregory ; Czuczman, Myron S. ; Hernandez-Ilizaliturri, Francisco J. ; Hong, Fredrick ; Sood, Raman ; Soniwala, Saif ; Lawrence, William ; Jamshed, Saad ; Masood, Aisha ; Iancu, Daniel ; Lee, Kelvin ; Chanan Khan, Asher A. / A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. In: British Journal of Haematology. 2011 ; Vol. 154, No. 1. pp. 104-110.
@article{48a77f45bbe0410e8756c78b3df85171,
title = "A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients",
abstract = "Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other anti-myeloma agents, these compounds significantly enhance clinical efficacy. High-dose steroids are frequently used in anti-myeloma combination regimens; however, the doses employed are often poorly tolerated, especially in patients with concurrent comorbid conditions. We hypothesized that a steroid-independent combination regimen could be developed without significant compromise of efficacy. The availability of such a regimen will be important for patients whose concurrent ailments make them poor candidates for steroid containing anti-myeloma regimens. A phase II single institute, non-randomized clinical trial was conducted to investigate a novel steroid-free three-drug combination of bortezomib (V), pegylated liposomal doxorubicin (D), and thalidomide (T), the VDT regimen. Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study. The overall response rate and complete response (CR)+near complete response (nCR) rate was 78{\%} and 35{\%}, respectively. Median time to progression was 29·5months. Fatigue, rash, neuropathy, constipation and infections were the most common side effects. We concluded that VDT is a tolerable and an effective regimen capable of inducing high response rates and can be employed in patients considered to be poor candidates for steroid-based treatment regimens.",
keywords = "Clinical trials, Multiple myeloma, Newly diagnosed multiple myeloma, Steroids, Thalidomide",
author = "Taimur Sher and Sikander Ailawadhi and Miller, {Kena C.} and Debbie Manfredi and Margaret Wood and Wei Tan and Gregory Wilding and Czuczman, {Myron S.} and Hernandez-Ilizaliturri, {Francisco J.} and Fredrick Hong and Raman Sood and Saif Soniwala and William Lawrence and Saad Jamshed and Aisha Masood and Daniel Iancu and Kelvin Lee and {Chanan Khan}, {Asher A}",
year = "2011",
month = "7",
doi = "10.1111/j.1365-2141.2011.08703.x",
language = "English (US)",
volume = "154",
pages = "104--110",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

AU - Sher, Taimur

AU - Ailawadhi, Sikander

AU - Miller, Kena C.

AU - Manfredi, Debbie

AU - Wood, Margaret

AU - Tan, Wei

AU - Wilding, Gregory

AU - Czuczman, Myron S.

AU - Hernandez-Ilizaliturri, Francisco J.

AU - Hong, Fredrick

AU - Sood, Raman

AU - Soniwala, Saif

AU - Lawrence, William

AU - Jamshed, Saad

AU - Masood, Aisha

AU - Iancu, Daniel

AU - Lee, Kelvin

AU - Chanan Khan, Asher A

PY - 2011/7

Y1 - 2011/7

N2 - Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other anti-myeloma agents, these compounds significantly enhance clinical efficacy. High-dose steroids are frequently used in anti-myeloma combination regimens; however, the doses employed are often poorly tolerated, especially in patients with concurrent comorbid conditions. We hypothesized that a steroid-independent combination regimen could be developed without significant compromise of efficacy. The availability of such a regimen will be important for patients whose concurrent ailments make them poor candidates for steroid containing anti-myeloma regimens. A phase II single institute, non-randomized clinical trial was conducted to investigate a novel steroid-free three-drug combination of bortezomib (V), pegylated liposomal doxorubicin (D), and thalidomide (T), the VDT regimen. Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study. The overall response rate and complete response (CR)+near complete response (nCR) rate was 78% and 35%, respectively. Median time to progression was 29·5months. Fatigue, rash, neuropathy, constipation and infections were the most common side effects. We concluded that VDT is a tolerable and an effective regimen capable of inducing high response rates and can be employed in patients considered to be poor candidates for steroid-based treatment regimens.

AB - Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other anti-myeloma agents, these compounds significantly enhance clinical efficacy. High-dose steroids are frequently used in anti-myeloma combination regimens; however, the doses employed are often poorly tolerated, especially in patients with concurrent comorbid conditions. We hypothesized that a steroid-independent combination regimen could be developed without significant compromise of efficacy. The availability of such a regimen will be important for patients whose concurrent ailments make them poor candidates for steroid containing anti-myeloma regimens. A phase II single institute, non-randomized clinical trial was conducted to investigate a novel steroid-free three-drug combination of bortezomib (V), pegylated liposomal doxorubicin (D), and thalidomide (T), the VDT regimen. Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study. The overall response rate and complete response (CR)+near complete response (nCR) rate was 78% and 35%, respectively. Median time to progression was 29·5months. Fatigue, rash, neuropathy, constipation and infections were the most common side effects. We concluded that VDT is a tolerable and an effective regimen capable of inducing high response rates and can be employed in patients considered to be poor candidates for steroid-based treatment regimens.

KW - Clinical trials

KW - Multiple myeloma

KW - Newly diagnosed multiple myeloma

KW - Steroids

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=79958789571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958789571&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08703.x

DO - 10.1111/j.1365-2141.2011.08703.x

M3 - Article

C2 - 21554260

AN - SCOPUS:79958789571

VL - 154

SP - 104

EP - 110

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -